Literature DB >> 6822026

Hemodynamic effects of intravenous labetalol in essential hypertension.

F G Dunn, W Oigman, F H Messerli, G R Dreslinski, E Reisin, E D Frohlich.   

Abstract

Labetalol inhibits alpha- and beta-adrenergic receptors. Systemic and regional hemodynamic alterations after intravenous labetalol and its cardiovascular reflexive and metabolic effects were evaluated in 12 subjects with mild to moderately severe essential hypertension. Supine systolic, diastolic, and mean pressures were reduced (from 180/101 and 125 to 149/86 and 109 mm Hg; P less than 0.001). The fall was accentuated during head-up tilt and was accompanied by decreased cardiac output and central blood volume in subjects in both the supine and tilted positions. Neither heart rate nor total peripheral resistance was changed by labetalol, suggesting that venodilation resulting from alpha-adrenergic-receptor inhibition played an important role in arterial pressure reduction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6822026     DOI: 10.1038/clpt.1983.21

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.

Authors:  D P Nicholls; J McNeill; P C O'Connor; D W Harron; W J Leahey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

Review 2.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 3.  Comparative tolerability profile of hypertensive crisis treatments.

Authors:  E Grossman; A N Ironi; F H Messerli
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

4.  Guidelines for the drug treatment of hypertensive crises.

Authors:  M M Hirschl
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

5.  Hypertension.

Authors:  Edward D. Frohlich
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.